Abstract
Epidemiological studies have demonstrated an inverse correlation between plasma concentrations of highdensity lipoprotein cholesterol (HDL-C) and incidence of coronary heart disease (CHD); thus new therapies for raising HDL-C levels have been the focus of significant efforts by the cardiovascular medicine community. Inhibition of cholesteryl ester transfer protein (CETP) is one approach to increasing HDL-C concentrations. CETP is a plasma glycoprotein that mediates the transfer of cholesteryl esters from HDL to the apoB-containing lipoproteins, with a balanced transfer of triglycerides. Inhibition of CETP results in an accumulation of cholesteryl esters in HDL, thus resulting in increased HDL-C. Pharmacological inhibition of CETP in humans has been shown to result in increased levels of HDL-C, although any beneficial effect of this inhibition on CHD has yet to be established. This review article will discuss the complex role of CETP in lipid metabolism, recent developments for small-molecule inhibitors of CETP, and future prospects for CETP inhibitors in the treatment of CHD.
Keywords: Atherosclerosis, CETP inhibitor, cholesteryl ester transfer protein, coronary heart disease, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol
Current Topics in Medicinal Chemistry
Title: Cholesteryl Ester Transfer Protein (CETP) Inhibitors
Volume: 9 Issue: 5
Author(s): Julianne A. Hunt and Zhijian Lu
Affiliation:
Keywords: Atherosclerosis, CETP inhibitor, cholesteryl ester transfer protein, coronary heart disease, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol
Abstract: Epidemiological studies have demonstrated an inverse correlation between plasma concentrations of highdensity lipoprotein cholesterol (HDL-C) and incidence of coronary heart disease (CHD); thus new therapies for raising HDL-C levels have been the focus of significant efforts by the cardiovascular medicine community. Inhibition of cholesteryl ester transfer protein (CETP) is one approach to increasing HDL-C concentrations. CETP is a plasma glycoprotein that mediates the transfer of cholesteryl esters from HDL to the apoB-containing lipoproteins, with a balanced transfer of triglycerides. Inhibition of CETP results in an accumulation of cholesteryl esters in HDL, thus resulting in increased HDL-C. Pharmacological inhibition of CETP in humans has been shown to result in increased levels of HDL-C, although any beneficial effect of this inhibition on CHD has yet to be established. This review article will discuss the complex role of CETP in lipid metabolism, recent developments for small-molecule inhibitors of CETP, and future prospects for CETP inhibitors in the treatment of CHD.
Export Options
About this article
Cite this article as:
Hunt A. Julianne and Lu Zhijian, Cholesteryl Ester Transfer Protein (CETP) Inhibitors, Current Topics in Medicinal Chemistry 2009; 9 (5) . https://dx.doi.org/10.2174/156802609788340823
DOI https://dx.doi.org/10.2174/156802609788340823 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Therapeutic Approaches in Inflammatory Bowel Disease
Current Pharmaceutical Design Phenolics and Terpenoids; the Promising New Search for Anthelmintics: A Critical Review
Mini-Reviews in Medicinal Chemistry Diabetes Mellitus, Hypertension and Hypercholesterolemia in Relation to the 10-Year ACS Prognosis; the GREECS Study
Current Vascular Pharmacology Cardiac Monitoring in Patients with Syncope: Making that Elusive Diagnosis
Current Cardiology Reviews Coenzyme Q10: A Potential Adjunct for Treatment of Antiphospholipid Syndrome and Recurrent Miscarriage
Current Immunology Reviews (Discontinued) Serum Levels of IL-6, TNF-α and IL-10 as Early Predictors of Mortality in Trauma Hemorrhagic Shock Patients
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Inorganic Nanoparticles for In Vitro Cancer Diagnosis: A Patent Review
Recent Patents on Nanomedicine Reactive Oxygen-Induced Cardiac Intracellular Pathways During Ischemia and Reperfusion
Current Signal Transduction Therapy The Developing Role of Neuregulin1 In Cardiac Regenerative Stem Cell Therapy
Current Pharmaceutical Design Can Untargeted Metabolomics Be Utilized in Drug Discovery/Development?
Current Topics in Medicinal Chemistry Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews Encapsulation of Plant-derived Bioactive Ingredients through Electrospraying for Nutraceuticals and Functional Foods Applications
Current Medicinal Chemistry Stabilization of Neutral NH2-R-COOH Form of the Antihypertensive Peptides L-Valyl-L-Prolyl-L-Proline and L-Isoleucyl-L-Prolyl-L-Proline
Protein & Peptide Letters Valproate and Neuroendocrine Changes in Relation to Women Treated for Epilepsy and Bipolar Disorder: A Review
Current Medicinal Chemistry A Novel and Significant Method for Antioxidant Activity Utilizing Microtitre-plate (Resazurin Reducing Power Assay)
Current Chemical Biology Hydrogels in Tissue Engineering: Scope and Applications
Current Pharmaceutical Biotechnology Atorvastatin-Loaded Oleic Acid Nanoglobules for Oral Administration: In Vitro Characterization and Biopharmaceutical Evaluation
Current Nanoscience Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology Super-Resolution Based Enhancement of Cardiac MR Images
Current Medical Imaging Mast Cell Chymase and Tryptase as Targets for Cardiovascular and Metabolic Diseases
Current Pharmaceutical Design